Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel

AIDS

Volumn 14, Issue 8, 2000, Pages 1009-1015

  Wegner, Scott A ^a,i   Brodine, Stephanie K ^b   Mascola, John R ^a   Tasker, Sybil A ^b   Shaffer, Richard A ^b   Starkey, Monica J ^c   Barile, Anthony ^d   Martin, Gregory J ^d   Aronson, Naomi ^d   Emmons, Wesley W ^e   Stephan, Kevin ^f   Bloor, Stuart ^h   Vingerhoets, Johan ^g   Hertogs, Kurt ^g   Larder, Brendan ^h  

^a US Military HIV Research Program   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^f WILFORD HALL MEDICAL CENTER   (United States)

^g Virco BVBA   (Belgium)

^h Virco UK Ltd   (United Kingdom)

ⁱ WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Drug resistance; Genotype; HIV; Phenotype

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; POL PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; COHORT ANALYSIS; DATA BASE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEROCONVERSION; SOLDIER; STRUCTURAL GENE; UNITED STATES; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; GENES, POL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MILITARY PERSONNEL; MUTATION; PHENOTYPE; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; UNITED STATES;

EID: 0034074743     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005260-00013     Document Type: Article

References (29)

1. 1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280: 78-86.
2. 2. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
3. 3. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998, 12:1619-1624.
4. 4. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
5. 5. Condra JH, Schleif WA, Blahy OM, et. al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
6. 6. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996, 70:7894-7899.
7. 7. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA 1998, 279:1984-1991.
8. 8. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
9. 9. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:1163-1165.
10. 10. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
11. 11. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997, 175:1502-1506.
12. 12. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
13. 13. U.S. Center for Disease Control. Initial therapy for tuberculosis in the era of multidrug resistsance-recommendations of the advisory council for the elimination of tuberculosis. MMWR 1993, 42(rr-7): 001.
14. 14. Erbelding E, Quinn TC. The impact of antimicrobial resistance on the treatment of sequally transmitted diseases. Infect Dis Clin 1997, 11:889-903.
15. 15. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282:1135-1141.
16. 16. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142-1149.
17. 17. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354:729-733.
18. 18. Brodine SK, Shaffer RA, Starkey MJ, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999, 31:502-506.
19. 19. Hertogs K, Larder B, Mellors J, et al. Patterns of phenotypic and genotypic cross-resistance among protease inhibitors in over 1000 clinical HIV-1 isolates. 12th World AIDS Conference. Geneva, July 1998 [abstract 42195].
20. 20. Hertogs K, de Bethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
21. 21. Pauwels R, Hertogs K, Kemp S, et al. Comprehensive HIV drug resistance monitoring using rapid, hig-throughput phenotypic and genotypic assays with correlative data analysis. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, June 1998 [abstract 51].
22. 22. Mayers DL, Yerly S, Perrin L, et al. Prevalence and clinical course of persons seroconverting with AZT-resistant HIV-1 in Switzerland, Australia, and the United States between 1988 and 1994. AIDS Res Hum Retrovirol 1995, 11 (suppl 1):S162.
23. 23. Rubio A, Leal M, Pineda JA, et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV010infected anti-viral naive patients from 1989 to 1996. AIDS 1997, 11:835-836.
24. 24. Conway B, Montessori V, Rouleau D, et al. Primary lamivudine resistance in acute HIV infection. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St. Petersburg, Florida, June 1997 [abstract 103].
25. 25. De Oliveira CF, Machado DM, Rawal BD, et. al. Resistance to nucleoside-analog antiretroviral drugs among blood donors recently infected with HIV-1 and naive to antiretroviral treatment. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 672].
26. 26. Yerly S, Rakik A, De Loes SK, et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998, 72:3520-3523.
27. 27. Birk M, Sonnerborg A. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS 1998, 12:2369-2375.
28. 28. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996, 2:753-759.
29. 29. Najera I, Holguin A, Quinones-Mateu ME, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.